Fulcrum Therapeutics, Sanofi Ink Losmapimod Licensing Deal
By Colin Kellaher
Fulcrum Therapeutics has licensed the international rights to its proposed treatment for a rare, genetic muscular disorder to France's Sanofi in a deal potentially worth more than $1 billion to the clinical-stage biopharmaceutical company.
Fulcrum on Monday said it will work with Sanofi on the development and commercialization of losmapimod, which is currently in Phase 3 studies for the treatment of facioscapulohumeral muscular dystrophy, a chronic and progressive disorder characterized by significant muscle cell death and fat infiltration into muscle tissue.
Fulcrum said it will receive an up-front payment of $80 million from Sanofi and will be eligible to receive up to an additional $975 million in regulatory and sales-based milestones.
The agreement gives Sanofi exclusive commercialization rights for losmapimod outside the U.S., while Fulcrum, based in Cambridge, Mass., retains full U.S. commercialization rights.
Fulcrum said it will received tiered escalating royalties starting in the low teens on sales of losmapimod outside the U.S., adding that the two companies will equally share future global development costs of the drug.
Fulcrum said it expects to report top-line data from its Phase 3 study of losmapimod by the end of the year.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 13, 2024 06:37 ET (10:37 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Is It Time to Ditch Your Money Market Fund for Longer-Term Bonds?
-
What’s Happening In the Markets This Week
-
4 Reasons Why Today’s Stock Market Is Delivering Impressive Performance
-
What Does Nvidia’s Stock Split Mean for Investors?
-
5 Undervalued Stocks to Buy as Their Stories Play Out
-
Markets Brief: Return of the Meme Stocks
-
It’s Been a Terrible Time for Bonds. Here’s Why You Should Own Them
-
Which AI Stocks Are Turning Hype Into Revenue?
-
Tesla: Shareholder Vote Reduces Key Person Risk
-
After Earnings, Is CrowdStrike Stock a Buy, a Sell, or Fairly Valued?
-
Adobe’s Strong Quarterly Results Drive Share Gains
-
What Does Broadcom’s Stock Split Mean for Investors?
-
5 Ultracheap Stocks to Buy With the Best Returns on Investment
-
Broadcom Earnings: AI Sales Growth Accelerates
-
Oracle Earnings: IaaS Signings More Than Make Up for Miss
-
This Undervalued Stock Is a Buy After Its Dividend Increase